J & J Faces Federal Subpoenas on Asbestos in Its Baby Powder
Johnson & Johnson executives this week revealed the Department of Justice and the Securities and Exchange Commission issued subpoenas related to ongoing lawsuits over the company’s alleged asbestos contamination in its popular talcum powder. The company disclosed the federal inquiries in its annual report to the SEC on Wednesday. It was the first time the pharmaceutical giant admitted that federal agencies had subpoenaed the company about its talc products. Despite thousands of lawsuits and a 2017 report that showed J&J executives were aware of the asbestos liabilities since the 1970s, company officials deny ...
Source: Asbestos and Mesothelioma News - February 22, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

New Immunotherapy Clinical Trial Targets Common Mesothelioma Protein
A biotechnology company specializing in innovative cancer therapeutics has opened a clinical trial examining an immunotherapy drug targeting a protein found in 90 percent of malignant mesothelioma tumors. It is the first clinical trial to specifically study a patient population characterized by this protein expression. The target is known as VISTA, a surface protein which inhibits the immune system from working properly and allows the mesothelioma to grow. The drug is CA-170, an orally available molecule and the only anti-VISTA drug being studied today in a cancer clinical trial. And the potential could be huge. “The...
Source: Asbestos and Mesothelioma News - February 19, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Dr. Mags Portman, HIV Prevention Pioneer, Dies from Mesothelioma at 44
Dr. Mags Portman, a British trailblazer in the fight to prevent and control HIV, died Wednesday after a two-year battle with mesothelioma. She was 44. Portman was lauded for triggering a significant reduction in HIV diagnoses throughout the United Kingdom by her work as a researcher, clinician and outspoken advocate. She earned international acclaim for her work as an HIV consultant at London’s Mortimer Market Centre, a progressive sexual health clinic that made pre-exposure prophylaxis (PrEP) a reality in the U.K. Portman played a key role in the 2014 study at The Royal London Hospital that proved the efficacy of t...
Source: Asbestos and Mesothelioma News - February 14, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

J & J Talc Supplier Imerys Files for Bankruptcy Over Cancer Lawsuits
Seeking protection from rapidly mounting litigation, Imerys Talc America and two of its subsidiaries filed for Chapter 11 bankruptcy protection Wednesday in Delaware. Imerys is a major talc supplier for Johnson & Johnson consumer goods, including the company’s iconic baby powder and Shower to Shower line. Litigants claim the talc-based products were contaminated with asbestos, leading to cases of mesothelioma and ovarian cancer. The bankruptcy filing comes in the midst of an ongoing, high-profile trial in California in which a woman is blaming Imerys talc for her mesothelioma, a rare cancer caused almost exclus...
Source: Asbestos and Mesothelioma News - February 14, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Chemo-Carrying Gold Nanoparticles Tested on Mesothelioma
Italian researchers have found early success using gold nanoparticles as a chemotherapy-delivery vehicle for mesothelioma. They are hopeful their discovery will lead to an improvement in mesothelioma treatment in the future. The researchers tested their strategy on pleural mesothelioma cells in the lab. They first designed gold nanoparticles with a specific antibody targeted to the cells. Then they loaded the chemotherapy drug Alimta (pemetrexed) into the nanoparticles and observed its effect on the cancer cells. Delivering Alimta through the gold nanoparticles proved more effective than standard chemotherapy. But the me...
Source: Asbestos and Mesothelioma News - February 12, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Mesothelioma Immunotherapy Combination Gaining Momentum
Recent studies from France and the Netherlands have shown patients with pleural mesothelioma can benefit significantly from a second-line immunotherapy drug combination. In separate phase II studies, the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) created a synergy that helped stop or slow tumor growth after traditional chemotherapy had failed. “Our results add to the growing evidence that immunotherapy is a promising treatment,” wrote lead author Dr. Maria Disselhorst of the Netherlands Cancer Institute in Amsterdam. “The combination of nivolumab plus ipilimumab showed marked efficacy in pa...
Source: Asbestos and Mesothelioma News - February 11, 2019 Category: Environmental Health Authors: Daniel King Source Type: news

State Attorneys General Push for Tougher Asbestos Reporting Rule
A coalition of 15 attorneys general are calling for a tougher asbestos reporting rule as part of the recently-revised Toxic Substances Control Act. Maine’s newly elected Attorney General Aaron Frey said last week the coalition wants to eliminate the exemptions for asbestos within the current Chemical Data Reporting guidelines. The attorneys general have asked U.S. Environmental Protection Agency Acting Administrator Andrew Wheeler to initiate a new rulemaking process, helping it comply with their interpretation of the legislation. “This [new] rule would allow the EPA to comply with the Act by giving it the info...
Source: Asbestos and Mesothelioma News - February 6, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Senator Probing Johnson & Johnson About Asbestos in Talc
Sen. Patty Murray, D-Wash., has questions, and she wants answers from Johnson & Johnson about its iconic baby powder and the reported link to asbestos-related cancers. Murray recently sent a letter to Johnson & Johnson CEO Alex Gorsky, asking for documentation about past testing for asbestos-tainted talc and communication with the FDA regarding the safety of its product. Murray is a ranking member of the Senate Committee on Health, Education, Labor and Pensions. The letter stemmed from an earlier report by Reuters that Johnson & Johnson hid evidence of asbestos in its product for many years and intentionally mi...
Source: Asbestos and Mesothelioma News - February 4, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Apatinib Case Study Uncovers Potential Mesothelioma Treatment
Doctors in China may have uncovered an effective second- or third-line treatment option for patients with malignant pleural mesothelioma. Dr. RongQin Meng, an oncologist at 363 Hospital in Cheng Du, said the investigational drug Apatinib (rivoceranib) could become part of a much-needed advance in mesothelioma treatment. After first- and second-line chemotherapy combinations had failed to slow tumor growth in a 58-year-old woman, Apatinib provided a five-month progression-free survival. “I was surprised at the result,” Meng told The Mesothelioma Center at Asbestos.com. “After taking the drug, the quality o...
Source: Asbestos and Mesothelioma News - January 31, 2019 Category: Environmental Health Authors: Daniel King Source Type: news

Combined Modality Treatment in Mesothelioma Combined Modality Treatment in Mesothelioma
Is combined modality treatment using surgery, radiotherapy and/or chemotherapy improving outcomes in malignant mesothelioma?Translational Lung Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 30, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Gene-Editing Tool Reverses Cancer Resistance to Chemotherapy
A team of researchers at the Gene Editing Institute in Newark, Delaware, has successfully treated chemotherapy-resistant lung cancer cells with the CRISPR gene-editing technique. The study was published Dec. 21, 2018, in Molecular Therapy Oncolytics. In addition to making drug-resistant lung cancer cells treatable with chemotherapy, the approach offers the potential to improve quality of life for cancer patients. “In the broader sense, such an approach would ultimately lead to a reduced level of chemotherapy required to produce the same tumor-killing activity, leading to an improvement in the quality of life of a can...
Source: Asbestos and Mesothelioma News - January 28, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Vaccine and Chemotherapy Combo Shows Promise for Mesothelioma
Mesothelioma patients showed an impressive immune response to TroVax, a novel cancer vaccine, when it was combined with standard chemotherapy in a recent clinical trial. Researchers from Cardiff University in the United Kingdom conducted the study that was published by the journal OncoImmunology. TroVax is a laboratory engineered virus designed to target the human protein 5T4. A mutated form of 5T4 is found in almost all mesothelioma tumors, including the sarcomatoid subtype, the most difficult to treat. The phase II clinical trial produced a disease control rate of 87 percent, more than double the rate of a previous stud...
Source: Asbestos and Mesothelioma News - January 22, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Mesothelioma Researchers Seek More Effectiveness from Immunotherapy
The objective-response rate was 9 percent, which included one patient with a complete response and disappearance of all tumor burden, and four patients with a partial response. Of the 48 patients whose data were assessed for change in tumor size, 24 experienced a reduction of some level. Most encouraging were the patients with a higher-level of PD-L1. They had a median overall survival of 20.2 months and a 12-month overall survival of 72.5 percent. PD-L1 presence alone, though, is not considered the only factor in how well the drug would work. Other factors such as genetic mutations of the tumor and mesothelioma cell type ...
Source: Asbestos and Mesothelioma News - January 17, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Congress Funds Feasibility Study for Mesothelioma Patient Registry
The National Institute for Occupational Safety and Health will oversee a study in 2019 to determine the feasibility of establishing the first national mesothelioma patient registry. The $100,000 feasibility study was part of the $1.2 million Congress allocated in 2019 to the Centers of Disease Control and Prevention for mesothelioma research. The bulk of the funding goes toward the National Mesothelioma Virtual Bank, which is a biospecimen registry first established in 2006. It is the only federally funded program designed exclusively for the research of mesothelioma, the rare and aggressive cancer caused by asbestos expos...
Source: Asbestos and Mesothelioma News - January 15, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Avelumab May Benefit Some Patients With Advanced Unresectable Mesothelioma Avelumab May Benefit Some Patients With Advanced Unresectable Mesothelioma
The anti-programmed cell death ligand 1 (PD-L1) monoclonal antibody avelumab is well tolerated and shows antitumor activity in some patients with previously treated unresectable mesothelioma, according to results from a single-arm trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 15, 2019 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Mesothelioma Symposium Brings Specialists and Survivors Together
Some of the nation’s top mesothelioma specialists are scheduled to share their expertise at the 2019 International Symposium on Malignant Mesothelioma. The event, organized by the Mesothelioma Applied Research Foundation, will be held March 24-27 in Bethesda, Maryland. The three-day symposium consists of two days of conference sessions and an advocacy day March 27. Mesothelioma patients, caregivers, family members and the bereaved community are invited to attend and learn about the latest treatment options for this rare cancer. “The symposium is a unique event for mesothelioma patients, their families and careg...
Source: Asbestos and Mesothelioma News - January 9, 2019 Category: Environmental Health Authors: Daniel King Source Type: news

Boston Scientific shares tick up after Q4 prelims meet estimates | Wall Street Beat
Shares in Boston Scientific (NYSE:BSX) rose slightly this morning after the company reported preliminary results for the fourth quarter and full year of 2018 that were in-line with estimates on Wall Street. The Marlborough, Mass.-based company said it expects to report $2.56 billion in sales for the fourth quarter and $9.82 billion for the full year. In Q4, Boston Scientific’s cardiovascular business pulled in $970 million in sales, while its rhythm & neuro unit recorded $790 million in revenue. The company’s MedSurg division saw $800 million in sales, according to an SEC filing. Most of the company&rs...
Source: Mass Device - January 8, 2019 Category: Medical Devices Authors: Sarah Faulkner Tags: Business/Financial News Featured MassDevice Earnings Roundup Wall Street Beat Alphatec Boston Scientific Hologic ICON plc Integra LifeSciences NovoCure Orthofix SeaSpine Source Type: news

Debate Continues on When Best to Use Mesothelioma Chemotherapy
This study is pretty reassuring that half the patients aren’t getting a more optimal or superior approach,” Simone said. “Both are good, accepted approaches. It’s more what the institution is comfortable with, and how the doctors are trained to do it.” European Trial May Be More Definitive The ongoing clinical trial is being done at centers in Belgium, France and the Netherlands. The European Organization for Research and Treatment of Cancer is sponsoring the study. The goal is 64 patients, half of whom will undergo pleurectomy and decortication surgery followed by three cycles of pemetrexed a...
Source: Asbestos and Mesothelioma News - January 3, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Chemotherapy Strategies in Malignant Pleural Mesothelioma Chemotherapy Strategies in Malignant Pleural Mesothelioma
Is immunotherapy beneficial in patients with progressive malignant pleural mesothelioma after initial platinum-based chemotherapy?Translational Lung Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 31, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Top 10 Mesothelioma and Asbestos News Stories of 2018
The death of renowned thoracic surgeon Dr. David Sugarbaker stunned the mesothelioma community, while asbestos awareness reached new heights in 2018. The loss of Sugarbaker, who pioneered mesothelioma treatment advances through three decades, was devastating to so many that he touched. On the other side, companies that continue to ignore the dangers of toxic asbestos were exposed — in the courtroom and in news coverage — about the problems they caused. Toxic asbestos was found in cosmetics, crayons and on the hands of executives at Johnson & Johnson, which is already paying the price. Here are the 10 most c...
Source: Asbestos and Mesothelioma News - December 20, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Documentary About Mesothelioma and Asbestos Exposure Now Streaming
The 2018 documentary “Dirty Laundry” is now available for the world to see. In the film, cousins Conor B. Lewis and Zack Johnson cycle more than 4,000 miles from California to New York, fueled by curiosity about their beloved grandmother’s surprise death to mesothelioma. Lewis and Johnson scour the country in search of others affected by this rare cancer caused by asbestos exposure, interviewing surviving family members, doctors, activists and residents living in Libby, Montana, and Ambler, Pennsylvania — two infamous EPA Superfund sites for asbestos cleanup. The film uncovers the harsh reality tha...
Source: Asbestos and Mesothelioma News - December 19, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Clinical Trial Tests CAR T-Cell Therapy on Peritoneal Mesothelioma
The National Cancer Institute in Rockville, Maryland, has opened an innovative clinical trial for patients with peritoneal mesothelioma that will explore the safety and effectiveness of a novel CAR T-cell therapy. The phase I trial also is being conducted at Washington University in St. Louis. It is aimed at patients whose disease has relapsed after initial chemotherapy treatment. It involves a laboratory modification of a patient’s T cells — a type of white blood cell — that can help the immune system kill the cancer. CAR T-cell therapy is a form of gene therapy that has been highly successful with blood...
Source: Asbestos and Mesothelioma News - December 18, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Asbestos Opens New Legal Front in Battle Over Johnson ’ s Baby Powder
Johnson& Johnson says its product is safe. But asbestos, a carcinogen that can exist underground near talc, was a concern inside the company for decades. (Source: NYT Health)
Source: NYT Health - December 15, 2018 Category: Consumer Health News Authors: RONI CARYN RABIN and TIFFANY HSU Tags: Asbestos Hazardous and Toxic Substances Product Tests Ovarian Cancer Suits and Litigation (Civil) Mesothelioma Cosmetics and Toiletries Research Johnson & Food and Drug Administration Source Type: news

Johnson & Johnson Feared Baby Powder ’ s Possible Asbestos Link for Years
Johnson& Johnson says its product is safe. But asbestos, a carcinogen that can exist underground near talc, was a concern inside the company for decades. (Source: NYT Health)
Source: NYT Health - December 15, 2018 Category: Consumer Health News Authors: RONI CARYN RABIN and TIFFANY HSU Tags: Johnson & Cosmetics and Toiletries Asbestos Hazardous and Toxic Substances Product Tests Ovarian Cancer Mesothelioma Suits and Litigation (Civil) Research Food and Drug Administration Babies and Infants Source Type: news

Baby Powder ’ s Possible Asbestos Link Worried Johnson & Johnson for Years
Johnson& Johnson says its product is safe. But asbestos, a carcinogen that can exist underground near talc, was a concern inside the company for decades. (Source: NYT Health)
Source: NYT Health - December 15, 2018 Category: Consumer Health News Authors: RONI CARYN RABIN and TIFFANY HSU Tags: Johnson & Cosmetics and Toiletries Asbestos Hazardous and Toxic Substances Product Tests Ovarian Cancer Mesothelioma Suits and Litigation (Civil) Research Food and Drug Administration Babies and Infants Source Type: news

In Battle Over Johnson ’ s Baby Powder, Asbestos Opens a New Legal Front
Johnson& Johnson says its product is safe. But asbestos, a carcinogen that can exist underground near talc, was a concern inside the company for decades. (Source: NYT Health)
Source: NYT Health - December 15, 2018 Category: Consumer Health News Authors: RONI CARYN RABIN and TIFFANY HSU Tags: Asbestos Hazardous and Toxic Substances Product Tests Ovarian Cancer Suits and Litigation (Civil) Mesothelioma Cosmetics and Toiletries Research Johnson & Food and Drug Administration Source Type: news

Science Saturday: Discovery advances potential individualized treatment for mesothelioma
Large chromosomal rearrangements present in mesothelioma could make it possible to understand which patients are likely respond to immunotherapy,? researchers at the?Mayo Clinic Center for Individualized Medicine? have discovered. The?research?is published in the?Journal of Thoracic Oncology. ?What we?ve shown so far is that these large complex chromosomal rearrangements are frequent in mesothelioma and may provide [...] (Source: Mayo Clinic Research News)
Source: Mayo Clinic Research News - December 15, 2018 Category: Research Source Type: news

Johnson & Johnson Knew of Asbestos in Talc for Decades
Investors responded negatively to an extensive report Friday that Johnson & Johnson knew for decades that its iconic baby powder could be contaminated with asbestos fibers but failed to warn the public or inform regulators. Shares of Johnson & Johnson stock dropped by 10 percent Friday, its worst loss in almost two decades, dealing the company a serious financial setback. Reuters News Service detailed internal documents, company memos and extensive conversations that contradicted previous claims by Johnson & Johnson that its Shower to Shower and Baby Powder products were beyond reproach. Johnson & Johnson a...
Source: Asbestos and Mesothelioma News - December 14, 2018 Category: Environmental Health Authors: Walter Pacheco Source Type: news

Johnson & Johnson Knew of Asbestos in Baby Powder for Decades
Investors responded negatively to an extensive report Friday that Johnson & Johnson knew for decades that its iconic baby powder could be contaminated with asbestos fibers but failed to warn the public or inform regulators. Shares of Johnson & Johnson stock dropped by 10 percent Friday, its worst loss in almost two decades, dealing the company a serious financial setback. Reuters News Service detailed internal documents, company memos and extensive conversations that contradicted previous claims by Johnson & Johnson that its Shower to Shower and Baby Powder products were beyond reproach. Johnson & Johnson a...
Source: Asbestos and Mesothelioma News - December 14, 2018 Category: Environmental Health Authors: Walter Pacheco Source Type: news

Cancer Incidence Rising Rapidly Around the World
More than 30,000 people around the world will be diagnosed with malignant mesothelioma cancer in 2018, according to the latest estimates by the International Agency for Research on Cancer. Almost 26,000 will die from the disease. The numbers on mesothelioma were part of a larger report that included 36 types of cancer. The research covered 185 countries throughout 20 regions. It was published in the November/December issue of CA: A Cancer Journal for Clinicians. An estimated 18.1 million new cancer cases and 9.6 million cancer deaths are expected in 2018, a significant rise from 2012, when the agency published its last stu...
Source: Asbestos and Mesothelioma News - December 13, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

Bittersweet Ending to Asbestos Cleanup in Libby, Montana
The asbestos cleanup of Libby, Montana, is coming to a celebrated close. The U.S. Environmental Protection Agency will soon end the largest, longest-running asbestos cleanup project in American history. It’s a bittersweet ending to what is left behind. The 19-year, $600 million EPA Superfund project aimed to right the wrongs created by the shuttered W.R. Grace and Co. vermiculite mine. Once the lifeblood of the community, it also became a cold-hearted killer. Although the mine was closed almost 30 years ago, health officials have since documented more than 400 deaths linked to asbestos-related diseases such as mes...
Source: Asbestos and Mesothelioma News - December 11, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Asbestos is in nine out of ten NHS hospitals
Sexual health consultant Mags Portman, 44, (pictured) was diagnosed with mesothelioma after working at  Law Hospital in south Lanarkshire, Scotland for more than 20 years. (Source: the Mail online | Health)
Source: the Mail online | Health - December 10, 2018 Category: Consumer Health News Source Type: news

Early Screening Key to Reducing Lung Cancer Deaths
Radiation oncologist Dr. Andrea McKee believes deaths from lung cancer — including those related to asbestos exposure — could be reduced significantly by increased utilization of early CT screening. McKee, chair of radiation oncology at Lahey Hospital and Medical Center in Burlington, Maine, has been a strong proponent of early screening for several years. “We could be saving tens of thousands of lives every year with this,” McKee told The Mesothelioma Center at Asbestos.com. “There is nothing else like it. The life-saving potential is the most important thing that has happened to cancer in my...
Source: Asbestos and Mesothelioma News - December 4, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Study Shows Cancer Patients Can Benefit from Opioid Switching
Switching from one prescription opioid to another often solves the problem of debilitating side effects or inadequate pain relief, according to a recent study involving a wide range of cancer patients. Opioids are not all the same. And neither are those they are helping. Despite the increasing government restrictions and the frenzy over potential abuse, opioids can be a lifesaver for a mesothelioma patient finding the right fit. “I’ve been through both sides of that switching issue,” said Tim Crisler, a 16-year pleural mesothelioma survivor told The Mesothelioma Center at Asbestos.com. “It worked gr...
Source: Asbestos and Mesothelioma News - November 26, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Abramson Developing CAR T-Cell Therapy for Mesothelioma
The National Cancer Institute awarded a five-year, $10.7 million grant to the Abramson Cancer Center at the University of Pennsylvania to develop CAR T-cell therapy for mesothelioma and lung cancer. The hopes are high for a breakthrough. The program involves a laboratory modification of a patient’s T cells — a type of white blood cell — that prompts the immune system to attack cancer cells. The therapy also is known as chimeric antigen receptor T-cell therapy. It already is revolutionizing the way some blood and bone marrow cancers are treated. The grant is designed to investigate whether this type of gen...
Source: Asbestos and Mesothelioma News - November 20, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Mesothelioma Patients Can Benefit from Genetic Testing
All patients diagnosed with malignant mesothelioma should undergo genetic testing to better identify the most appropriate treatment plan, according to Dr. Michele Carbone, the director of thoracic oncology at the University of Hawaii Cancer Center. Genetic testing also could lead to a more accurate prognosis and help family members determine if they are more susceptible to the cancer. Carbone estimates only one-third of all mesothelioma patients today have undergone the testing. “Some of these patients could definitely benefit from genetic testing,” Carbone told The Mesothelioma Center at Asbestos.com. Carbon...
Source: Asbestos and Mesothelioma News - November 13, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Department of Justice Looking Closer at Asbestos Trusts
The U.S. Department of Justice has increased its scrutiny of asbestos trust funds in recent months, urging more accountability and transparency. Those who administer the funds believe they work just fine. The trust funds are designed mostly to compensate workers who were sickened by negligent companies that sold or manufactured asbestos products. Currently there are more than 60 trust funds with an estimated $30 billion combined, stemming from companies seeking bankruptcy protection and avoiding future liabilities related to asbestos exposure. Since the first trust was established in 1988, they have paid out more than $20 ...
Source: Asbestos and Mesothelioma News - November 7, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Alimta-Related Skin Reactions with and Without Oral Steroids
This study supports the use of intravenous dexamethasone 10 mg before pemetrexed infusion in place of three days of oral dexamethasone 4 mg twice daily at UNMCCC,” the authors wrote. The post Alimta-Related Skin Reactions with and Without Oral Steroids appeared first on Mesothelioma Center - Vital Services for Cancer Patients & Families. (Source: Asbestos and Mesothelioma News)
Source: Asbestos and Mesothelioma News - November 5, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Radiation Could Make Mesothelioma Immunotherapy More Effective
Doctors at the Princess Margaret Cancer Center in Toronto are studying the use of hypofractionated radiation to increase the effectiveness of immunotherapy for patients with mesothelioma. They are expected to launch soon a clinical trial that will add an immunotherapy combination to the high-dose radiation and aggressive surgery mix that has been so successful in Toronto. “There are a lot of questions that still need to be answered, but if I was a betting man, I’d lay odds on it [working well],” Dr. John Cho of the cancer center’s clinical research unit, told The Mesothelioma Center at Asbestos.com....
Source: Asbestos and Mesothelioma News - November 2, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

French Study Reveals Potential Mesothelioma Treatment Target
A team of French researchers led by Dr. Christophe Blanquart has identified a substance that may better define the severity of malignant pleural mesothelioma (MPM) in the body and provide clues to more effectively manage the rare cancer. Brain-derived neurotrophic factor, as the name indicates, is a protein found in the brain. BDNF is a growth factor and also appears in other tissues in the body. “It seems that BDNF could be a prognostic marker for MPM patients,” Blanquart told The Mesothelioma Center at Asbestos.com. “The level of BDNF in pleural fluids could reflect the severity of disease.” The...
Source: Asbestos and Mesothelioma News - October 31, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

NovoCure slides on Q3 sales miss
NovoCure (NSDQ:NVCR) shares took a hit today, despite lower-than-forecast losses, after the company reported financial results that missed expectations for third-quarter sales. Losses were up 1.7% to -$11.7 million, or -13¢ per share, on sales growth of 29.2% to $64.8 million for the three months ended Sept. 30, compared with Q3 2017. The consensus estimate on Wall Street was for losses of -15¢ on sales of $65.4 million. “We delivered record quarterly revenue of $64.8 million in the third quarter, representing 5% quarter-over-quarter growth, driven by both active patient growth and ongoing improve...
Source: Mass Device - October 25, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Drug-Device Combinations MassDevice Earnings Roundup Wall Street Beat NovoCure Source Type: news

Pioneering UK nursing post created for asbestos-related cancer
Samantha Westbrook has been appointed as the first peritoneal mesothelioma clinical nurse specialist in the UK. (Source: Nursing Times)
Source: Nursing Times - October 25, 2018 Category: Nursing Source Type: news

U.S. Asbestos Imports Surge in August, Report Finds
The amount of raw chrysotile asbestos imported into the United States increased significantly between July and August, according to a recent analysis from the Asbestos Disease Awareness Organization and the Environmental Working Group. The U.S. International Trade Commission and Department of Commerce provided the two advocacy organizations the data for their report. According to the investigation, the U.S. imported 272 metric tons (approximately 600,000 pounds) of asbestos in August — an increase of nearly 2,000 percent from the 13 metric tons in July. EWG and ADAO on Tuesday attributed the alarming spike to the g...
Source: Asbestos and Mesothelioma News - October 24, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Mesothelioma Early Detection Getting Closer with Blood Test
German scientists are advancing a new, more reliable blood test that could lead to earlier detection and better prognosis for malignant mesothelioma. Instead of the typically lengthy and invasive process, the simple blood test could identify early stage disease almost a year before symptoms appear, making it much more treatable. The advancement stems from a study analyzing a combination of calretinin and mesothelin, two blood-based proteins that are overexpressed when mesothelioma tumors start growing. “This is a real breakthrough,” biochemist Dr. Georg Johnen, lead study researcher and head of Molecular Medici...
Source: Asbestos and Mesothelioma News - October 23, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Penn researchers land $10.7M grant to study CAR-T cell therapy in solid tumors
The University of Pennsylvania's Abramson Cancer Center had received a $10.7 million grant from the National Cancer Institute to study CAR-T cells in solid tumors The five-year grant from the NCI's will support new experimental approaches in lung cancer and mesothelioma being conducted by Penn researchers at its translational center of excellence for lung cancer immunology “Although CAR-T cells have been revolutionized the treatment of leukemia and bone marrow cancers, we have not yet had the… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - October 22, 2018 Category: American Health Authors: John George Source Type: news

Penn researchers land $10.7M grant to study CAR-T cell therapy in solid tumors
The University of Pennsylvania's Abramson Cancer Center had received a $10.7 million grant from the National Cancer Institute to study CAR-T cells in solid tumors The five-year grant from the NCI's will support new experimental approaches in lung cancer and mesothelioma being conducted by Penn researchers at its translational center of excellence for lung cancer immunology “Although CAR-T cells have been revolutionized the treatment of leukemia and bone marrow cancers, we have not yet had the… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - October 22, 2018 Category: Biotechnology Authors: John George Source Type: news

Canada Announces Ban of Asbestos, But with Exemptions
The Canadian government released the final draft last week of its much-anticipated ban on asbestos, making it illegal to import, manufacture, sell, trade or use products made with the toxic mineral. The ban, which goes into effect Dec. 30, 2018, contains exemptions that still allow its use in the chlor-alkali industry, the military, nuclear facilities and for magnesium extraction from asbestos mining residue. It will be known as The Prohibition of Asbestos and Products Containing Asbestos Regulations. Canadian Environment Minister Catherine McKenna touted the tough new regulations during the announcement, but critics stil...
Source: Asbestos and Mesothelioma News - October 22, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Canada Announces Asbestos Ban with Exemptions
The Canadian government released the final draft last week of its much-anticipated ban on asbestos, making it illegal to import, manufacture, sell, trade or use products made with the toxic mineral. The ban, which goes into effect Dec. 30, 2018, contains exemptions that still allow its use in the chlor-alkali industry, the military, nuclear facilities and for magnesium extraction from asbestos mining residue. It will be known as The Prohibition of Asbestos and Products Containing Asbestos Regulations. Canadian Environment Minister Catherine McKenna touted the tough new regulations during the announcement, but critics stil...
Source: Asbestos and Mesothelioma News - October 22, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Study Highlights Surgery Benefits of P/D over EPP for Mesothelioma
This study focused on 30-day mortality and postoperative complications. It included a meta-analysis of 39 previous studies from 1990 to 2017, along with the New York Statewide Planning and Research Cooperative System database from 1995 to 2012. Study results included: 30 Day Mortality: EPP 5 percent; P/D 2 percent Postoperative Complications: EPP 46 percent; P/D 24 percent Postoperative Arrhythmias: EPP 20 percent; P/D 5 percent. Although there is no cure for pleural mesothelioma, aggressive surgery — with either the P/D or EPP — has been proven to extend survival times. According to a recent study pub...
Source: Asbestos and Mesothelioma News - October 19, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

UK Study Matches Mesothelioma Treatments to Genetic Profile
University of Leicester researchers soon will open the first molecularly stratified clinical trial for malignant mesothelioma with the hope of moving the future of treatment toward more personalization. The phase II trial in the United Kingdom is designed to match therapy with a patient’s specific genetic profile. “We’re trying to bring the right drug to the right patient at the right time,” Professor Dean Fennell, chair of thoracic medical oncology at Leicester and chief trial investigator, told Asbestos.com. “We need to find different treatments that work for different people. This is a step...
Source: Asbestos and Mesothelioma News - October 12, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news